C De Nunzio1, G Truscelli2, A Trucchi1, S Petta1, M Tubaro3, M Gacci4, C Gaudio2, F Presicce1, A Tubaro1. 1. Department of Urology, Ospedale Sant'Andrea, 'Sapienza' University of Rome, Rome, Italy. 2. Department of Heart and Great Vessels 'A. Reale', Policlinico Umberto I, ' Sapienza' University of Rome, Rome, Italy. 3. ICCU, Cardiovascular Department, Ospedale San Filippo Neri, Rome, Italy. 4. Department of Urology, Ospedale Careggi, University of Florence, Florence, Italy.
Abstract
BACKGROUND: Smoking, hypertension, abdominal obesity and metabolic abnormalities have been considered individual factors involved in prostate cancer (PCa) pathogenesis. All of these factors are used to define the individual cardiovascular risk (CVR). The aim of our study was to evaluate the association between CVR and PCa diagnosis and grade among a consecutive series of men undergoing prostate biopsy. METHODS: From 2010 onwards, consecutive patients undergoing 12-core prostate biopsy were enrolled. Body mass index was measured before the biopsy. Blood samples were collected and tested for: PSA, fasting glucose, triglycerides and high-density lipoproteins. Blood pressure was also recorded. Metabolic syndrome was defined according to the Adult Treatment Panel III and CVR according to the European Association of Cardiologist Guidelines. We evaluated the association between CVR and PCa biopsy Gleason score using logistic regression analyses. RESULTS: Five hundred and eighty-four patients were enrolled. Four hundred and six patients (70%) presented a moderate/high CVR. Two hundred and thirty-seven (40.6%) patients had cancer on biopsy; 157 with moderate/high CVR and 80 with low/no CVR (P=0.11). Out of the 237 patients with PCa, 113 had a Gleason score 6 and 124 a Gleason score ⩾7. Out of them, 92/124 (75%) presented a moderate/high CVR (P=0.004). Moderate/high CVR was not associated with an increased risk of PCa (odds ratio (OR): 0.741, confidence interval (CI): 0.474-1.156; P=0.186) but with an increased risk of Gleason score ⩾7 (OR: 2.154, CI: 1.076-4.314; P=0.030). CONCLUSIONS: In our study, a moderate/high CVR is associated with an increased risk of a high-grade Gleason score when PCa is diagnosed on biopsy. Although these results should be confirmed in multicentre studies, patients with moderate/high CVR should be carefully evaluated for PCa diagnosis.
BACKGROUND: Smoking, hypertension, abdominal obesity and metabolic abnormalities have been considered individual factors involved in prostate cancer (PCa) pathogenesis. All of these factors are used to define the individual cardiovascular risk (CVR). The aim of our study was to evaluate the association between CVR and PCa diagnosis and grade among a consecutive series of men undergoing prostate biopsy. METHODS: From 2010 onwards, consecutive patients undergoing 12-core prostate biopsy were enrolled. Body mass index was measured before the biopsy. Blood samples were collected and tested for: PSA, fasting glucose, triglycerides and high-density lipoproteins. Blood pressure was also recorded. Metabolic syndrome was defined according to the Adult Treatment Panel III and CVR according to the European Association of Cardiologist Guidelines. We evaluated the association between CVR and PCa biopsy Gleason score using logistic regression analyses. RESULTS: Five hundred and eighty-four patients were enrolled. Four hundred and six patients (70%) presented a moderate/high CVR. Two hundred and thirty-seven (40.6%) patients had cancer on biopsy; 157 with moderate/high CVR and 80 with low/no CVR (P=0.11). Out of the 237 patients with PCa, 113 had a Gleason score 6 and 124 a Gleason score ⩾7. Out of them, 92/124 (75%) presented a moderate/high CVR (P=0.004). Moderate/high CVR was not associated with an increased risk of PCa (odds ratio (OR): 0.741, confidence interval (CI): 0.474-1.156; P=0.186) but with an increased risk of Gleason score ⩾7 (OR: 2.154, CI: 1.076-4.314; P=0.030). CONCLUSIONS: In our study, a moderate/high CVR is associated with an increased risk of a high-grade Gleason score when PCa is diagnosed on biopsy. Although these results should be confirmed in multicentre studies, patients with moderate/high CVR should be carefully evaluated for PCa diagnosis.
Authors: Cosimo De Nunzio; Stephen J Freedland; Roberto Miano; Alberto Trucchi; Andrea Cantiani; Alfonso Carluccini; Andrea Tubaro Journal: Prostate Date: 2011-02-25 Impact factor: 4.104
Authors: K Esposito; P Chiodini; A Capuano; G Bellastella; M I Maiorino; E Parretta; A Lenzi; D Giugliano Journal: J Endocrinol Invest Date: 2013-02 Impact factor: 4.256
Authors: Richard M Martin; Lars Vatten; David Gunnell; Pål Romundstad; Tom I L Nilsen Journal: Cancer Causes Control Date: 2009-03-11 Impact factor: 2.506
Authors: Thomas Sehestedt; Jørgen Jeppesen; Tine W Hansen; Susanne Rasmussen; Kristian Wachtell; Hans Ibsen; Christian Torp-Pedersen; Michael H Olsen Journal: J Hypertens Date: 2009-12 Impact factor: 4.844
Authors: Anne Berghöfer; Tobias Pischon; Thomas Reinhold; Caroline M Apovian; Arya M Sharma; Stefan N Willich Journal: BMC Public Health Date: 2008-06-05 Impact factor: 3.295
Authors: Antonio Cicione; Aldo Brassetti; Riccardo Lombardo; Antonio Franco; Beatrice Turchi; Simone D'Annunzio; Antonio Nacchia; Andrea Tubaro; Giuseppe Simone; Cosimo De Nunzio Journal: Cancers (Basel) Date: 2022-02-14 Impact factor: 6.639
Authors: Cosimo De Nunzio; Giuseppe Simone; Aldo Brassetti; Riccardo Mastroianni; Devis Collura; Giovanni Muto; Michele Gallucci; Andrea Tubaro Journal: BMC Cancer Date: 2016-07-07 Impact factor: 4.430